Ali Amid, MD
Thursday, September 26, 2024, 8:00-9:00 am (San Francisco)
In this session:
Alpha thalassemia major was once considered a fatal condition, but with advances in perinatal care, more patients with this condition are surviving into adulthood. Given the rarity of this condition, our treatment has generally been based on strategies for beta thalassemia, though important differences warrant a unique approach. In this presentation, we will discuss our current treatment approach for these patients and review uncertainties that warrant further research.
–
The International Alpha Thalassemia Consortium brings together an interdisciplinary group of clinicians and scientists from around the world to focus expertise in hematology, maternal-fetal medicine, genetics, fetal therapy, and neonatology on alpha thalassemia major (ATM).
We gather quarterly to share advances, challenges, and best practices regarding clinical care for prenatal, pediatric, and adult patients diagnosed with ATM. Each session lasts one hour, including a 30-minute presentation, followed by moderated discussion.
